BioNTech Heads to ASCO With $1 Billion Buyback and a Stock Down 15% in a Month

BioNTech arrives at ASCO with a $1B buyback and €16.8B cash, but weak Q1 sales and a 15% stock drop heighten stakes for upcoming ADC clinical data.

BioNTech arrives at the American Society of Clinical Oncology’s annual meeting this week carrying a freshly announced $1 billion share repurchase programme and a stock that has shed roughly 15% of its value over the past month. The buyback, which runs through May 2027 and is funded from a cash pile of nearly €16.8 billion, signals management’s confidence in the oncology pivot. But for investors, the real test begins on 29 May, when the company unveils clinical data on its antibody-drug conjugate (ADC) portfolio and other pipeline assets at the Chicago conference.

The urgency of the ASCO readouts is underscored by a weak first quarter. Revenue plunged to €118.1 million from €182.8 million a year earlier, driven by a halving of Covid-19 vaccine sales to just €66.9 million. Research and development costs surged to €557 million, pushing the net loss to €531.9 million – nearly €532 million. Despite the burn rate, the company’s liquidity cushion – over €16.8 billion in cash and securities – leaves ample room for the ambitious oncology buildout.

At ASCO, BioNTech will present two oral talks and four poster sessions. The spotlight falls on its ADC candidates, with data expected in advanced solid tumours, prostate cancer, and uterine cancer. These presentations are part of a broader late-stage push: the company has flagged seven pivotal data packages for 2026, aims to have 15 phase 3 studies running by year-end, and ultimately expects at least 17 late-stage readouts by 2030 across lung, breast, gynaecological, and head-and-neck cancers.

To streamline operations, BioNTech is restructuring its manufacturing footprint. Sites in Idar-Oberstein, Marburg, and Tübingen are slated for closure by the end of 2027, and the Singapore facility will shut in the first quarter of 2027. The company is exploring sale options for all four locations and targets annual cost savings of around €500 million once the restructuring is complete.

Analyst opinion remains split despite a consensus buy rating from 17 analysts. The average price target stands at $125.45, implying roughly 38% upside from current levels, but the range is wide. J.P. Morgan maintains a neutral stance, while Canaccord recently trimmed its target to $158 from $171 but kept a buy recommendation.

The stock closed at €79.50 on Friday, more than 22% below its 52-week high and trading decisively under its 200-day moving average. For US investors, the trading week starts on a shortened schedule – Wall Street is closed on Monday for Memorial Day – compressing the window to position ahead of ASCO’s first data releases.

What emerges from Chicago will determine whether BioNTech’s oncology pipeline is more than a collection of promises. The company’s financial heft buys time, but convincing clinical data on the ADC and broader platform are needed to justify the heavy spending and restore momentum to a stock that has lost more than 15% in a month.